Resources
32 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/26/2021 (updated 4/10/2024)
Posted 5/26/2021 (updated 4/10/2024)
Posted 5/26/2021 (updated 4/10/2024)
What is the importance of responsive leadership? The complex choices facing leaders at every level of an organization require inclusive assessments and innovative solutions. Leaders face questions about who should be sitting around the table and which two or three responses might work to address a community consortium challenge. The presenter will review interventions for engaging in complex situations and a new normal.
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 3/25/2021 (updated 4/5/2024)
Documentation, Coding, and Billing for SUD/OUD via Medication-Assisted Treatment (MAT): A Rural and Community Health Focus
The presenter will outline the steps needed to effectively document, code, and bill for services including screening for SUD/OUD and providing care during the induction, stabilization, and maintenance phases of MAT. Individual state Medicaid issues are too numerous and will not be specifically referred to on a state-by-state basis.
Posted 3/25/2021 (updated 4/5/2024)
Recovery Housing, Medications for OUD (MOUD), and Emerging Issues
Presenters will explain recovery housing and MOUD in the context of issues emerging in rural America resulting from the pandemic and its impact on the rates of substance use disorder (SUD) and drug overdose. They will discuss the impact of the pandemic on the correctional system and state actions in response to COVID-19 as it affects those with SUD. They will also give an overview of how recovery housing can be developed, especially in rural areas.
Posted 3/25/2021 (updated 4/5/2024)
Effective Harm Reduction Strategies for People Who Actively Use Opioids and/or Psychostimulants
Participants will learn evidenced-based harm reduction strategies to keep people who use opioids and psychostimulants alive with reduced disease burden. Presenters will discuss methods of engaging people who actively use opioids and/or psychostimulants, harm reduction interventions, overdose prevention and response, overamping prevention and response, and linkages to care.
Posted 12/15/2020 (updated 4/3/2024)
This presentation discussed the evolution of North Carolina’s formerly siloed sectors: prevention, treatment, & recovery. The introduction of Recovery Community Center (RCC) funding helped to develop a network of community-based recovery support services. However, when one of NC’s strongest prevention coalitions received RCC funding, they took it to another level. Keeping strongly rooted in its prevention identity, they expanded their growth into authentic recovery support services and non-arrest diversion partnerships with local law enforcement and treatment providers. Implementation II grantee Wilson Substance Prevention Coalition illustrated some of its full continuum of care programming and how it has adapted to the pandemic’s challenges